Qin Liu
- Biomaterials top 5%
- Nanoparticle-Based Drug Delivery 6
- Immunology top 10%
- Immunotherapy and Immune Responses 20
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers 16
- CAR-T cell therapy research 6
- Biotechnology top 5%
- Cancer Research and Treatments 11
-
- RNA Interference and Gene Delivery 7
-
- Monoclonal and Polyclonal Antibodies Research 6
-
- Nanoplatforms for cancer theranostics 6
- Cited by
- BiomaterialsImmunologyOncology
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Qin Liu
59 papers receiving 1.5k citations
Peers
Comparison fields: 5 of 100
- Biomaterials 381
- Immunology 422
- Oncology 468
- Biotechnology 109
- Molecular Biology 593
Countries citing papers authored by Qin Liu
This map shows the geographic impact of Qin Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qin Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qin Liu more than expected).
Fields of papers citing papers by Qin Liu
This network shows the impact of papers produced by Qin Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qin Liu. The network helps show where Qin Liu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Qin Liu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 5 | |
| 3 | 2024 | 10 | |
| 4 | 2024 | 2 | |
| 5 | 2024 | 1 | |
| 6 | 2023 | 14 | |
| 7 | 2023 | 2 | |
| 8 | 2023 | 7 | |
| 9 | 2023 | 1 | |
| 10 | 2023 | 4 | |
| 11 | 2022 | 65 | |
| 12 | 2022 | 9 | |
| 13 | 2022 | 40 | |
| 14 | 2021 | 8 | |
| 15 | 2020 | 38 | |
| 16 | 2020 | 27 | |
| 17 | 2019 | 223 | |
| 18 | 2018 | 47 | |
| 19 | 2013 | 40 | |
| 20 | 2012 | 12 |
About Qin Liu
Qin Liu is a scholar working on Biotechnology, Immunology and Oncology, having authored 62 papers that have together received 1.5k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (20 papers), Cancer Immunotherapy and Biomarkers (16 papers), Cancer Research and Treatments (11 papers), RNA Interference and Gene Delivery (7 papers), Nanoparticle-Based Drug Delivery (6 papers), Monoclonal and Polyclonal Antibodies Research (6 papers), Nanoplatforms for cancer theranostics (6 papers) and CAR-T cell therapy research (6 papers). The work is most often cited by research in Biomaterials (381 citations), Immunology (422 citations) and Oncology (468 citations). Qin Liu has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Baorui Liu, Rutian Li, Lixia Yu, Xiqun Jiang, Jia Wei, Jie Shen, Hanqing Qian, Xiaoping Qian, Huifang Su and Pingping Shen. Their work appears in journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.